CytomX Therapeutics (CTMX) Fundamentals 2026 — Revenue Analysis | SniperIQ
CytomX Therapeutics (CTMX) is a US-listed Healthcare company in Biotechnology with a market capitalization of $540M, trading at
CytomX Therapeutics (CTMX) has a market capitalization of approximately $540M, trading at
CytomX Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
CytomX Therapeutics runs a net profit margin of -166.4%, a gross margin of 99.3%, and an operating margin of -181.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
CytomX Therapeutics reported revenue of $76M for fiscal year 2025, with net income of -
CytomX Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
CytomX Therapeutics carries a debt-to-equity ratio of 0.01x and a current ratio of 10.38x, with a market beta of 2.08. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For CytomX Therapeutics (CTMX) the key facts are: market cap $540M, revenue $76M, 52-week range 1.72-8.21. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Get CytomX Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.